Video: Day 2 Highlights | ESC Congress 2019

Dr. Deepak Bhatt and Prof. Philippe Gabriel Steg discuss ticagrelor compared to placebo added to low-dose aspirin in patients with stale coronary artery disease (THEMIS and THEMIS-PCI—0:40); angiotensin receptor neprilysin inhibition in heart failure with preserved ejection fraction and dapagliflozin and prevention of adverse outcomes in heart failure (PARAGON-HF and DAPA HF—4:08); revascularization with multivessel percutaneous coronary intervention in ST-segment elevation myocardial infarction (COMPLETE—8:17); and ticagrelor versus prasugrel in patients with acute coronary syndrome (ISAR-REACT 5—9:40).

Engage with fellow ACC members by discussing this article and ESC Congress 2019 on ACC's Member Hub message board. Please log into ACC.org to participate. Not a member? Join the ACC today!

Clinical Topics: Acute Coronary Syndromes, Heart Failure and Cardiomyopathies, Invasive Cardiovascular Angiography and Intervention, Prevention, Atherosclerotic Disease (CAD/PAD), Acute Heart Failure, Interventions and ACS, Interventions and Coronary Artery Disease, Interventions and Imaging, Angiography, Nuclear Imaging

Keywords: ESC Congress, ESC 19, Adenosine, Primary Prevention, Angiography, Percutaneous Coronary Intervention, Diabetes Mellitus, Coronary Artery Disease, Angiotensins, Stroke Volume, Heart Failure, Diabetes Mellitus, Type 2, Stroke Volume, Heart Failure, Hospitalization, Glucosides, Benzhydryl Compounds, Cardiomyopathies, Myocardial Infarction, Percutaneous Coronary Intervention, Angiography, Acute Coronary Syndrome


< Back to Listings